About MedImmune
MedImmune is a company based in Gaithersburg (United States) founded in 1987 was acquired by Astrazeneca in April 2007. MedImmune has completed 5 acquisitions, including Allozyne, AlphaCore Pharma and Cellective Therapeutics. MedImmune operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
- Headquarter Gaithersburg, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$354.18 K (USD), Grant
Sep 01, 2018
-
Investors
Astrazeneca
& 1 more
-
Employee Count
Not available
-
Investments & Acquisitions
Allozyne
& 4 more
-
Acquired by
Astrazeneca
(Apr 23, 2007)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of MedImmune
Unlock access to complete
Unlock access to complete
Leadership Team
403 people
Software Development Team
205 people
Product Management Team
76 people
Data Analysis and Operations Team
68 people
Senior Team
67 people
Human Resources and Administration
63 people
Sales and Marketing
54 people
Operations Team
50 people
Unlock access to complete
Funding Insights of MedImmune
Investors in MedImmune
MedImmune has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Astrazeneca and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Pharmaceutical and biologics products are developed and distributed worldwide.
|
Locked | Locked | Locked |
Investor details for MedImmune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MedImmune
MedImmune has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Allozyne, AlphaCore Pharma and Cellective Therapeutics.
Investment portfolio details for MedImmune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develops protein therapeutics for treating cardiovascular diseases like atherosclerosis.
|
Locked | Locked | 2007 | Locked | |
|
Protein therapeutics for CNS diseases like multiple sclerosis are developed.
|
Locked | Locked | 2005 | Locked | |
|
B cell research for cancer and autoimmune diseases was conducted.
|
Locked | Locked | 2003 | Locked |
Complete acquisition details for MedImmune
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - MedImmune
Detailed financials for MedImmune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Medimmune Comparisons
Peer comparison for MedImmune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MedImmune
MedImmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
Detailed competitors of MedImmune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Medimmune
Complete news archive for MedImmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MedImmune
MedImmune was founded in 1987 and raised its 1st funding round 29 years after it was founded.
MedImmune is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Speck Loe is the current CEO of MedImmune.
MedImmune is a global biologic RD company developing product candidates for three therapeutic areas namely oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic disease. It was founded as Molecular Vaccines and has developed Flumist, a nasal spray influenza vaccine which was approved by FDA as a needle-free vaccine CAIV-T in 2007. In April 2007, AstraZeneca acquired MedImmune and since then it is working as its RD unit. In September 2009, MedImmune received approval from the U.S. FDA for its intranasal novel H1N1 influenza vaccine. Currently, it claims to have more than 120 biologics in RD and 40 products in clinical development.
MedImmune's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
MedImmune has made 5 acquisitions, including Allozyne, AlphaCore Pharma, and Cellective Therapeutics.
MedImmune has 2 investors. Key investors include Astrazeneca, and European Union.